SIC
IOVA icon

SJS Investment Consulting’s Iovance Biotherapeutics IOVA Stock Holding History

SJS Investment Consulting’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.22K Buy
533
+518
+3,453% +$1.97K ﹤0.01% 1735
2026
Q1 		$53 Buy
+15
New +$48 ﹤0.01% 2245
2025
Q1 		– Sell
-4
Closed -$30 – 1634
2024
Q4 		$30 Buy
+4
New +$37 ﹤0.01% 1576

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
MCP
Mirador Capital Partners Pleasanton, California $817M AUM 42.46% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

SJS Investment Consulting's IOVA Position: Q2 2026 in Review

SJS Investment Consulting increased its Iovance Biotherapeutics (IOVA) stake by 3,453% in Q2 2026, buying an estimated $1.97K and bringing the position to 533 shares worth $2.22K. The position accounts for ﹤0.01% of the portfolio, ranked #1735.

SJS Investment Consulting first reported a position in IOVA in Q4 2024 and has held it in 3 quarters since. 109 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • SJS Investment Consulting held 533 shares of Iovance Biotherapeutics worth $2.22K as of Q2 2026.
  • SJS Investment Consulting bought 518 Iovance Biotherapeutics shares in Q2 2026, an estimated $1.97K.
  • Iovance Biotherapeutics made up ﹤0.01% of SJS Investment Consulting's portfolio in Q2 2026, its #1735 holding.
  • SJS Investment Consulting first reported a position in Iovance Biotherapeutics in Q4 2024 and has held it in 3 quarters since.
  • 109 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on SJS Investment Consulting's 13F filing for Q2 2026, filed 22 Jul 2026.